ePrints

Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

Lookup NU author(s): Dr Nicholas Wadd, Dr Joseph Bozzino

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR = 53%; NC = 34.7%; PD = 12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.

Publication metadata

Author(s): Braun MS, Adab F, Bradley C, McAdam K, Thomas G, Wadd NJ, Rea D, Philips R, Twelves C, Bozzino J, MacMillan C, Saunders MP, Counsell R, Anderson H, McDonald A, Stewart J, Robinson A, Davies S, Richards FJ, Seymour MT

Publication type: Article

Publication status: Published

Journal: British Journal of Cancer

Year: 2003

Volume: 89

Issue: 7

Pages: 1155-1158

ISSN (print): 0007-0920

ISSN (electronic): 1532-1827

Publisher: Nature Publishing Group

URL: http://dx.doi.org/10.1038/sj.bjc.6601237

DOI: 10.1038/sj.bjc.6601237

Altmetrics

Share